Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Carboplatin + Paclitaxel & Non-small-cell lung carcinoma (NSCLC), the combination Carboplatin + Paclitaxel is an established, FDA‑approved regimen for the first‑line treatment of advanced or metastatic Non-small-cell lung carcinoma (NSCLC), including both squamous and non‑squamous subtypes (1).
The EMA‑approved Carboplatin + Paclitaxel for the first‑line treatment of non‑small‑cell lung cancer in adults who are not candidates for curative surgery or radiation, confirming regulatory approval for this doublet in NSCLC w…